vs
Side-by-side financial comparison of Moderna (MRNA) and Primerica, Inc. (PRI). Click either name above to swap in a different company.
Moderna is the larger business by last-quarter revenue ($1.0B vs $853.7M, roughly 1.2× Primerica, Inc.). Primerica, Inc. runs the higher net margin — 23.1% vs -19.7%, a 42.8% gap on every dollar of revenue. On growth, Primerica, Inc. posted the faster year-over-year revenue change (11.0% vs -45.4%). Over the past eight quarters, Primerica, Inc.'s revenue compounded faster (7.2% CAGR vs -45.0%).
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
Primerica, Inc. is a multi-level marketing company that provides insurance, investment and financial services to middle-income families in the United States and Canada.
MRNA vs PRI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $853.7M |
| Net Profit | $-200.0M | $197.0M |
| Gross Margin | 79.6% | — |
| Operating Margin | -25.6% | 28.9% |
| Net Margin | -19.7% | 23.1% |
| Revenue YoY | -45.4% | 11.0% |
| Net Profit YoY | -1638.5% | 17.9% |
| EPS (diluted) | $-0.51 | $6.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $853.7M | ||
| Q3 25 | $1.0B | $839.9M | ||
| Q2 25 | — | $793.3M | ||
| Q1 25 | — | $804.8M | ||
| Q4 24 | $966.0M | $768.8M | ||
| Q3 24 | $1.9B | $774.1M | ||
| Q2 24 | — | $803.4M | ||
| Q1 24 | — | $742.8M |
| Q4 25 | — | $197.0M | ||
| Q3 25 | $-200.0M | $206.8M | ||
| Q2 25 | — | $178.3M | ||
| Q1 25 | — | $169.1M | ||
| Q4 24 | $-1.1B | $167.1M | ||
| Q3 24 | $13.0M | $164.4M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | $137.9M |
| Q4 25 | — | — | ||
| Q3 25 | 79.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 23.5% | — | ||
| Q3 24 | 72.4% | — | ||
| Q2 24 | — | 98.0% | ||
| Q1 24 | — | 98.2% |
| Q4 25 | — | 28.9% | ||
| Q3 25 | -25.6% | 32.3% | ||
| Q2 25 | — | 29.6% | ||
| Q1 25 | — | 27.5% | ||
| Q4 24 | -129.0% | 64.7% | ||
| Q3 24 | -3.8% | 32.9% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 24.1% |
| Q4 25 | — | 23.1% | ||
| Q3 25 | -19.7% | 24.6% | ||
| Q2 25 | — | 22.5% | ||
| Q1 25 | — | 21.0% | ||
| Q4 24 | -115.9% | 21.7% | ||
| Q3 24 | 0.7% | 21.2% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 18.6% |
| Q4 25 | — | $6.11 | ||
| Q3 25 | $-0.51 | $6.35 | ||
| Q2 25 | — | $5.40 | ||
| Q1 25 | — | $5.05 | ||
| Q4 24 | $-2.91 | $4.92 | ||
| Q3 24 | $0.03 | $4.83 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $3.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $756.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.3B | $2.4B |
| Total Assets | $12.1B | $15.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $756.2M | ||
| Q3 25 | $1.1B | $644.9M | ||
| Q2 25 | — | $621.2M | ||
| Q1 25 | — | $625.1M | ||
| Q4 24 | $1.9B | $687.8M | ||
| Q3 24 | $1.6B | $550.1M | ||
| Q2 24 | — | $627.3M | ||
| Q1 24 | — | $593.4M |
| Q4 25 | — | $2.4B | ||
| Q3 25 | $9.3B | $2.3B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | $10.9B | $2.3B | ||
| Q3 24 | $11.9B | $1.9B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | — | $15.0B | ||
| Q3 25 | $12.1B | $14.8B | ||
| Q2 25 | — | $14.8B | ||
| Q1 25 | — | $14.6B | ||
| Q4 24 | $14.1B | $14.6B | ||
| Q3 24 | $15.8B | $14.8B | ||
| Q2 24 | — | $14.6B | ||
| Q1 24 | — | $14.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-847.0M | $338.2M |
| Free Cash FlowOCF − Capex | $-880.0M | — |
| FCF MarginFCF / Revenue | -86.6% | — |
| Capex IntensityCapex / Revenue | 3.2% | — |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $338.2M | ||
| Q3 25 | $-847.0M | $202.9M | ||
| Q2 25 | — | $162.6M | ||
| Q1 25 | — | $197.5M | ||
| Q4 24 | $825.0M | $270.6M | ||
| Q3 24 | $-1.6B | $207.3M | ||
| Q2 24 | — | $173.3M | ||
| Q1 24 | — | $210.9M |
| Q4 25 | — | — | ||
| Q3 25 | $-880.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $303.0M | — | ||
| Q3 24 | $-1.7B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -86.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 31.4% | — | ||
| Q3 24 | -92.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 3.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 8.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 0.98× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | 1.62× | ||
| Q3 24 | -120.46× | 1.26× | ||
| Q2 24 | — | 147.98× | ||
| Q1 24 | — | 1.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
PRI
| Revenues From Sources Other Than Contracts With Customers | $445.9M | 52% |
| Investment And Savings Products Segment Revenues | $340.3M | 40% |
| Other | $56.5M | 7% |
| Segment Revenues From Contracts With Customers | $11.0M | 1% |
